REFERENCES
- Novick AC, Fergany A. Renovascular hypertension and ischemic nephropathy. In: Walsh PC, Retik AB, Vaughan ED, , eds. Campells Urology. St. Louis, MO: WB Saunders; 2002:235–238
- Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther. 2004;26(Suppl A):A28–A32.
- Ewald S, vor dem Esche J, Uen S, Neikes F, Vetter H, Mengden T. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy: Results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study. Clin Drug Investig. 2006;26(8):439–446.
- Barrios V, Boccanelli A, Ewald S, Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: The OLMEBEST Study. Clin Drug Investig. 2007;27(8):545–558.
- Johansen TL, Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol. 2001;2:1.
- Cohen LS, Friedman EA. Losartan-induced azotemia in a diabetic recipient of a kidney transplant. N Engl J Med. 1996;334: 1271–1272.
- Holm EA, Randlov A, Strandgaard S. Brief report: Acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Press. 1996;5:360–362.